[Modification of coagulation factors during neonatal exchange transfusions].
Spears
R
R
Couchard
M
M
Relier
J P
JP
Jensen
A H
AH
Pinon
F
F
Sender
P
P
D000704:Analysis of Variance; D001663:Bilirubin / Q000097:blood; D001800:Blood Specimen Collection / Q000379:methods; D004899:Erythroblastosis, Fetal / Q000097:blood / Q000628:therapy; D005078:Exchange Transfusion, Whole Blood / Q000009:adverse effects* / Q000379:methods; D005165:Factor V / Q000378:metabolism*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism*; D005602:France; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000628:therapy; D015931:Intensive Care, Neonatal; D008991:Monitoring, Physiologic; D010976:Platelet Count; D011516:Prothrombin / Q000378:metabolism*; D012203:Rh Isoimmunization / Q000097:blood / Q000628:therapy; D013997:Time Factors
D005338:Fibrin Fibrinogen Degradation Products; D005165:Factor V; D011516:Prothrombin; D005340:Fibrinogen; D001663:Bilirubin